Long-acting second-generation antipsychotics, beyond efficacy: a 12-month prospective study on patients' attitudes towards treatment

被引：0
|
作者：
Pietrini, F. [1 ]
Spadafora, M. [1 ]
Talamba, G. A. [1 ]
Godini, L. [1 ]
Santangelo, A. [1 ]
Chiarello, F. [1 ]
Ballerini, A. [1 ]
机构：
[1] Univ Florence, Dept Neurosci Psychol Drug Res & Child Hlth, Sect Neurosci, Florence, Italy
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2014年 / 24卷
关键词：
SCHIZOPHRENIA;
D O I：
10.1016/S0924-977X(14)70918-6
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.f.013
引用
收藏
页码：S573 / S574
页数：2
相关论文
共 50 条
  • [1] New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia
    Citrome, Leslie
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (07) : 767 - 783
  • [2] Practical guidelines for the use of long-acting injectable second-generation antipsychotics
    Jarema, Marek
    Wichniak, Adam
    Dudek, Dominika
    Samochowiec, Jerzy
    Bienkowski, Przemyslaw
    Rybakowski, Janusz
    PSYCHIATRIA POLSKA, 2015, 49 (02) : 225 - 241
  • [3] Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study
    Magliocco, Fabio
    de Filippis, Renato
    Aloi, Matteo
    Staltari, Filippo Antonio
    Gaetano, Raffaele
    Segura-Garcia, Cristina
    De Fazio, Pasquale
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2020, 24 (02) : 201 - 207
  • [4] Longitudinal changes in antipsychotic dose in patients treated with long-acting injectable second-generation antipsychotics
    Nakajima, Nozomi
    Mizoe, Nao
    Misawa, Fuminari
    Yamashita, Toru
    So, Ryuhei
    Kitagawa, Kohei
    Tanimoto, Kenichi
    Kishi, Yoshiki
    Fujii, Yasuo
    Takeuchi, Hiroyoshi
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2021, 36 (02) : 84 - 88
  • [5] Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents
    Jann, Michael W.
    Penzak, Scott R.
    CNS DRUGS, 2018, 32 (03) : 241 - 257
  • [6] The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values
    Lee, Lik Hang N.
    Choi, Charles
    Collier, Abby C.
    Barr, Alasdair M.
    Honer, William G.
    Procyshyn, Ric M.
    CNS DRUGS, 2015, 29 (12) : 975 - 983
  • [7] Long-Acting Injectable Second-Generation Antipsychotics in Seriously Ill Patients with Schizophrenia: Doses, Plasma Levels, and Treatment Outcomes
    Fernandez-Miranda, Juan Jose
    Diaz-Fernandez, Silvia
    Cepeda-Piorno, Francisco Javier
    Lopez-Munoz, Francisco
    BIOMEDICINES, 2024, 12 (01)
  • [8] Second-Generation Long-Acting Injectable Antipsychotics and the Risk of Treatment Failure in a Population-Based Cohort
    Janzen, Donica
    Bolton, James M.
    Leong, Christine
    Kuo, I. fan
    Alessi-Severini, Silvia
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [9] Adding Suicide Prevention to the Triple Advantages of Injectable Long-Acting Second-Generation Antipsychotics
    Pompili, Maurizio
    FRONTIERS IN PSYCHIATRY, 2020, 10
  • [10] Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis
    Park, Seon-Cheol
    Choi, Mi Young
    Choi, Jina
    Park, Eunjung
    Tchoe, Ha Jin
    Suh, Jae Kyung
    Kim, Young Hoon
    Won, Seung Hee
    Chung, Young-Chul
    Bae, Kyung-Yeol
    Lee, Sang-Kyu
    Park, Chan Mi
    Lee, Seung-Hwan
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2018, 16 (04) : 361 - 375
12345